Open-label, Dose-escalation, Multiple Immunisation Study on the Safety, Tolerability and Immunogenicity of Lu AF20513 in Patients With Mild Alzheimer's Disease

Trial Profile

Open-label, Dose-escalation, Multiple Immunisation Study on the Safety, Tolerability and Immunogenicity of Lu AF20513 in Patients With Mild Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Lu AF20513 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 15 Mar 2017 Planned primary completion date changed from 1 May 2017 to 1 Oct 2018.
    • 15 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 28 Sep 2015 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top